CAMBRIDGE, MA--(Marketwire - June 20, 2012) - PharmaPros Corporation, a technology solutions provider for the life sciences industry, announced today the implementation of its Adapt Central product, an eClinical Data Hub, at Harvard Clinical Research Institute (HCRI), an Academic Research Organization. HCRI is using Adapt Central as an in-house, multi-source data hub to support its customized web-based clinical endpoint adjudication technology to enhance delivery of Clinical Events Committee (CEC) services.
HCRI is a leading provider of CEC services with an extensive network of board-certified physicians with expertise in various therapeutic disciplines. Looking to leverage technology to optimize delivery of CEC services, HCRI selected PharmaPros to develop advanced technology capabilities for the acquisition and collation of endpoint related data from a variety of clinical data sources, enabling face-to-face consensus or remote majority rule adjudications within the same clinical review web application.
"As a leader in clinical event adjudication, we are excited about this new technology, which we believe will add even further to our efficiency and quality. The ability to have electronic access to source documents, images, and case reports is a major advance for both our standard consensus face-to-face meetings as well as allow for involvement of physician experts in a variety of specialties who may not be able to attend a local meeting," said Donald Cutlip, MD, Executive Director of Clinical Investigations, Harvard Clinical Research Institute.
Adapt Central was configured to acquire and collate data from EDC, CDMS, Safety, and CTMS systems, as well as medical images and hospital records. Through abstraction and normalization of the source system data via the Adapt Central data hub, PharmaPros was able to deliver value through simplification of the clinical data collation process, normalize variability in multi-source data models, and develop a configurable, scalable clinical endpoint adjudication system to support HCRI's new web-based clinical adjudication technology.
"PharmaPros was very excited to work with HCRI to develop a flexible, automated solution to meet their business needs. Leveraging our existing technology in Adapt Central, and HCRI's extensive CEC experience, we were able to build a truly innovative solution. It was an excellent example of value-driven, agile development, which is our core software development philosophy," said Nick Neri, Vice President of Technology at PharmaPros.
PharmaPros Corporation (www.PharmaPros.com) is a technology solutions provider for the life sciences industry. The company's innovative approach and deep industry expertise have resulted in innovative solutions that are redefining clinical trials technology. PharmaPros is a leader in the emerging generation of cloud-based solutions for clinical trials. The company was formed in 1996, and is located in Cambridge, MA.
About Harvard Clinical Research Institute
Harvard Clinical Research Institute (HCRI, www.hcri.harvard.edu) designs and manages global clinical trials. HCRI leverages resources and engages medical experts from across the Harvard Medical School campus, adding unique value to clinical trial design and management, study management, statistical analyses, and CEC adjudication.
As a full-service academic research organization, HCRI offers all CRO services. HCRI's expertise spans many research-related fields such as biostatistics, data management, project management, clinical management, safety oversight, CEC services, and clinical site monitoring, as well as support services including data systems management and development, financial management, proposal development and quality assurance. HCRI's association with world-class scientific leaders in diverse areas of clinical research gives HCRI an intellectual edge. As HCRI continues to diversify its CEC service offerings and best-in-class endpoint adjudication process, the company looks forward to the rollout of a fully integrated web-enabled adjudication system in the early part of 2013.